1.2 million doses of China-made Covid-19 vaccine arrives in Indonesia

President Joko Widodo said in a televised address that another 1.8 million doses of the vaccine are expected to arrive in early January.
A man works in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China.(REUTERS)
A man works in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China.(REUTERS)
Published on Dec 06, 2020 09:39 PM IST
Copy Link
Associated Press | ByAssociated Press | Posted by Shankhyaneel Sarkar

Indonesia’s government said 1.2 million doses of a COVID-19 vaccine developed by China-based biopharmaceutical company Sinovac Biotech arrived in the country late Sunday.

President Joko Widodo said in a televised address that another 1.8 million doses of the vaccine are expected to arrive in early January.

“We are very grateful, thank God, the vaccine is now available so that we can immediately curb the spread of the COVID-19 disease,” Widodo said.

The government is still waiting for millions of other doses of the Sinovac vaccine to arrive in the form of raw materials that will be further processed by state-owned pharmaceutical holding company PT Bio Farma.

However, Widodo said that emergency use authorization from the country’s Food and Drug Control Agency is still needed for mass vaccinations to start.

Indonesia is already cooperating with Sinovac in phase 3 clinical trials of its vaccine candidate, with tests being carried out on 1,620 volunteers in West Java’s Bandung city since August. The government also looked into partnerships with two other Chinese drug manufacturers, Sinopharm and CanSino Biologics.

Penny Lukito, head of the Food and Drug Control Agency, estimated that the Sinovac vaccine would obtain emergency use authorization from the agency by the third or fourth week of January, after the agency evaluates interim results from the third-stage clinical trial.

SHARE THIS ARTICLE ON
Close Story
SHARE
Story Saved
OPEN APP
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Sunday, November 28, 2021